Kailera Therapeutics is a pioneering clinical-stage biopharmaceutical company focused on developing innovative GLP-1 therapies for obesity and related conditions. With a commitment to empowering individuals to improve their health, Kailera offers a differentiated portfolio of both injectable and oral treatments designed to support chronic weight management.

The brand boasts an advanced pipeline that includes promising candidates like KAI-9531, a dual GLP-1/GIP receptor agonist shown to have compelling efficacy in early-phase trials for obesity and type 2 diabetes. Additionally, Kailera is working on other innovative therapies, such as KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, a tri-agonist designed to offer comprehensive metabolic support.

Backed by experienced leadership and top-tier healthcare investors, Kailera strives to drive scientific excellence and deliver therapies that can transform the lives of those grappling with obesity and metabolic disorders. Their extensive research and clinical trials underscore a dedication to establishing best-in-class solutions in the fight against obesity.